Immunogenicity assessment of elder hepatocellular carcinoma patients after inactivated whole-virion SARS-CoV-2 vaccination

Safety and antibody response to inactivated COVID‐19 vaccine in patients with chronic hepatitis B virus infection

(2022) Taiyu He et al.   LIVER INTERNATIONAL

Humoral immune response of BBIBP COVID‐19 vaccination before and after the booster immunization

(2022) Zhangkai J. Cheng et al.   ALLERGY

Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study

(2022) Jitao Wang et al.   Hepatology International

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel

(2022) Yinon M. Bar-On et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron

(2022) Gili Regev-Yochay et al.   NEW ENGLAND JOURNAL OF MEDICINE

Booster shot of inactivated SARS‐CoV‐2 vaccine induces potent immune responses in people living with HIV

(2022) Haoting Zhan et al.   JOURNAL OF MEDICAL VIROLOGY

Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals

(2022) Yun Shan Goh et al.   Frontiers in Immunology

Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Hypertensive and/or Diabetic People Aged over 60 Years: A Prospective Open-Label Study

(2022) Rongdong Huang et al.   Diabetes Therapy

Serologic status and safety of inactivated Covid‐19 vaccine for hepatocellular carcinoma patients with cirrhosis after curative liver resection

(2022) Fuchen Liu et al.   Cancer Communications

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients

(2021) Markus Cornberg et al.   JOURNAL OF HEPATOLOGY

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

(2021) Leticia Monin et al.   LANCET ONCOLOGY

BNT162b2 COVID ‐19 vaccine is significantly less effective in patients with hematologic malignancies

(2021) Katrin Herzog Tzarfati et al.   AMERICAN JOURNAL OF HEMATOLOGY

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

(2021) Oliver Van Oekelen et al.   CANCER CELL

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults

(2021) Nawal Al Kaabi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS‐CoV‐2 vaccine

(2021) Lei Yue et al.   JOURNAL OF MEDICAL VIROLOGY

Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial

(2021) ShengLi Xia et al.   LANCET INFECTIOUS DISEASES

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

(2021) Dami A. Collier et al.   NATURE

Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients

(2021) Nora Liebers et al.   BLOOD

Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy

(2021) Mona Ariamanesh et al.   CANCER INVESTIGATION

Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter Study

(2021) Jingwen Ai et al.   Clinical Gastroenterology and Hepatology

Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment

(2021) Tania Buttiron Webber et al.   EUROPEAN JOURNAL OF CANCER

Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis

(2021) Andrea Becerril-Gaitan et al.   EUROPEAN JOURNAL OF CANCER

Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV

(2021) Zhengchao Lv et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers

(2021) Pinkus Tober-Lau et al.   Lancet Respiratory Medicine

Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment

(2021) A. Grinshpun et al.   ESMO Open

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

(2020) Nicole M Kuderer et al.   LANCET

Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study

(2020) Lewis Au et al.   CELL

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

(2020) Shengli Xia et al.   LANCET INFECTIOUS DISEASES

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

(2020) Ugur Sahin et al.   NATURE

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

(2020) Edward E. Walsh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited

(2020) Antoni Ribas et al.   Cancer Discovery